Neumora Therapeutics Reports on Shareholder Vote
Ticker: NMRA · Form: 8-K · Filed: Jun 14, 2024 · CIK: 1885522
| Field | Detail |
|---|---|
| Company | Neumora Therapeutics, INC. (NMRA) |
| Form Type | 8-K |
| Filed Date | Jun 14, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
TL;DR
Neumora had a shareholder vote on June 13th, details to follow.
AI Summary
Neumora Therapeutics, Inc. filed an 8-K on June 14, 2024, reporting on a matter submitted to a vote of its security holders on June 13, 2024. The company, formerly known as RBNC Therapeutics, Inc., is incorporated in Delaware and is involved in the biological products sector.
Why It Matters
This filing indicates a formal shareholder action, which could relate to significant corporate governance or strategic decisions impacting the company's future direction.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote without immediate financial or operational implications detailed.
Key Players & Entities
- Neumora Therapeutics, Inc. (company) — Registrant
- RBNC Therapeutics, Inc. (company) — Former company name
- June 13, 2024 (date) — Date of earliest event reported
- June 14, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific matter was submitted to a vote of Neumora Therapeutics' security holders?
The filing states that a matter was submitted to a vote of security holders on June 13, 2024, but does not specify the nature of the matter in this excerpt.
When did Neumora Therapeutics, Inc. change its name from RBNC Therapeutics, Inc.?
The date of the name change from RBNC Therapeutics, Inc. to Neumora Therapeutics, Inc. was September 29, 2021.
What is Neumora Therapeutics' principal executive office address?
The principal executive offices are located at 490 Arsenal Way, Suite 200, Watertown, Massachusetts 02472.
What is the SIC code for Neumora Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Neumora Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 615 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-06-14 16:01:03
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share NMRA The Nasdaq
Filing Documents
- d788157d8k.htm (8-K) — 30KB
- 0001193125-24-161572.txt ( ) — 153KB
- nmra-20240613.xsd (EX-101.SCH) — 3KB
- nmra-20240613_lab.xml (EX-101.LAB) — 18KB
- nmra-20240613_pre.xml (EX-101.PRE) — 11KB
- d788157d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUMORA THERAPEUTICS, INC. Date: June 14, 2024 By: /s/ Joshua Pinto, Ph.D. Joshua Pinto, Ph.D. Chief Financial Officer